Find information on common issues.
Ask questions and find answers from other users.
Suggest a new site feature or improvement.
Check on status of your tickets.
[Illinois] Cancer Community Symposium 2012: A Sensitivity Scale for Targeting T Cells with Chimeric Antigen Receptors (CAR) and Bispecific T Cell Engagers (BiTE)
09 May 2012 | | Contributor(s):: Jennifer Stone
Using a patients immune system to target cancer and maintain long-term surveillance is an attractive goal. Although T cells can respond potently to tumors, immune tolerance mechanisms often result in deletion or inactivation of those T cells expressing specific T cell receptors (TCRs) against...
[Illinois] Cancer Community Symposium 2012: DriveRank: Discovering Patient-Specific Driver Mutations
09 May 2012 | | Contributor(s):: Jack Pu Hou
One of the pressing challenges in cancer genomics is to distinguish driver mutations (i.e. mutations involved in tumorigenesis) and passenger mutations (i.e. functionally neutral mutations). Current approaches to identifying driver mutations in cancer look for recurrent events in multiple...
[Illinois] Cancer Community Symposium 2012: Elevated Estrogen Signaling Drives Tumorigenesis in a Novel Animal Model for Ovarian Epithelial Cancer
09 May 2012 | | Contributor(s):: Mary Jo Laws
We generated a mouse model where aberrant estrogen receptor alpha (Esr1) signaling in the hypothalamo-pituitary-ovarian axis leads to ovarian tumorigenesis. In this model, termed Esr1d/d, the Esr1 gene is selectively deleted in the anterior pituitary. The Esr1d/d mice form palpable ovarian tumors...
2005 Oncological Sciences Center Symposium
out of 5 stars
16 Aug 2005 |
Progress and Problems inCancer Treatment and Prevention
2005 Oncological Sciences Center Symposium Agenda
07 Dec 2006 |
2008 BioNano Technology and Pharmaceuticals
06 Aug 2008 | | Contributor(s):: Pankaj Sharma, Nalam Madhusudhana Rao
The purpose of this symposium is to bring together top scientists from India and the United States to present their latest work and to discuss future international scientific collaborative partnerships. This one and a half day symposium will also feature a special second half day mini-symposium...
Nov 16 2015
4th Oncology Partnering & Deal-Making Conference
Jul 07 2014
5th Cancer Targets & Therapeutics Conference
Antiestrogenic Conjugates as New Breast Cancer Chemoprevention Agents
08 Mar 2007 | | Contributor(s):: Ross Weatherman
Tamoxifen is the first drug specifically approved for the prevention of cancer and arguably the most successful anticancer drug of all time. Although millions of breast cancer patients have benefited from tamoxifen therapy, there are side effects that hinder the broad use of tamoxifen as a...
BME 695L Lecture 13: Designing Nanomedical Systems (NMS) for In-vivo Use
22 Nov 2011 | | Contributor(s):: James Leary
See references below for related reading.13.1 Bringing in-vivo considerations into NMS design13.1.1 the in-vitro to ex-vivo to in-vivo paradigm 18.104.22.168 In-vitro - importance of choosing...
BME 695L Lecture 14: Designing and Testing Integrated Nanomedical Systems
See references below for related reading.14.1 Introduction to integrated designs14.1.1 “Total design” but there is some order in the design process14.1.2 A brief outline of the total design...
BME 695L Special Lecture 3: In vivo Model Systems to Study Nanomedical Approaches to Cancer Detection and Intervention
02 Dec 2011 | | Contributor(s):: Deborah W Knapp
Guest lecturer: Deborah Knapp.
BME 695L: Engineering Nanomedical Systems
31 Aug 2011 | | Contributor(s):: James Leary
This course will cover the basic concepts of design of integrated nanomedical systems for diagnostics and therapeutics. Topics to be covered include: why nanomedical approaches are needed, cell targeting strategies, choice of core nanomaterials, technologies for testing composition and structure...
BME 695N Lecture 18: Designing nanodelivery systems for in-vivo use
12 Nov 2007 | | Contributor(s):: James Leary
Outline:Overview – the in-vitro to ex-vivo to in-vivo paradigm In-vitro - importance of choosing suitable cell lines Ex-vivo – adding the complexity of in-vivo background while keeping the simplicity of in-vitro In-vivo - all the complexity of ex-vivo plus the “active” components of a real...
BME 695N Lecture 19: In vivo model systems to study nanomedical approaches to cancer detection and intervention
27 Nov 2007 | | Contributor(s):: Deborah W Knapp
With Deborah Knapp as guest lecturer.
BME 695N: Engineering Nanomedical Systems (Fall 2007)
03 Aug 2007 | | Contributor(s):: James Leary
Cancer Care Engineering
31 Jan 2011 | | Contributor(s):: Joseph Pekny
Development of Highly Porous Large Polymeric Microparticles for Sustained Local Drug Delivery to the Lung
10 Jul 2008 | | Contributor(s):: Yoon Yeo
In this presentation, I will introduce a new way of making highly porous large polymeric microparticles recently developed in my lab. These microparticles exhibited desirable aerodynamic properties, reduced macrophage uptake, encapsulated a drug efficiently, and provided sustained drug release...
Functionalized Nanomaterials at the Interface of Biology and Technology
24 Apr 2008 | | Contributor(s):: Dean Ho, National Center for Learning & Teaching in Nanosca
Nanomaterials, such as block copolymeric membranes and nanodiamonds, can be engineered for a broad range of applications in energy and medicine. This presentation will highlight the relevance of these materials as foundations for device fabrication across the spectrum of biology and technology....